- Home
- PRAX vs ATLC Comparison
PRAX vs ATLC Comparison
Compare PRAX & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- ATLC
- Stock Information
- Founded
- PRAX 2015
- ATLC 1996
- Country
- PRAX United States
- ATLC United States
- Employees
- PRAX N/A
- ATLC N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- ATLC Finance: Consumer Services
- Sector
- PRAX Health Care
- ATLC Finance
- Exchange
- PRAX Nasdaq
- ATLC Nasdaq
- Market Cap
- PRAX 950.8M
- ATLC 766.4M
- IPO Year
- PRAX 2020
- ATLC 1999
- Fundamental
- Price
- PRAX $59.22
- ATLC $50.24
- Analyst Decision
- PRAX Strong Buy
- ATLC Buy
- Analyst Count
- PRAX 10
- ATLC 6
- Target Price
- PRAX $101.00
- ATLC $64.17
- AVG Volume (30 Days)
- PRAX 399.5K
- ATLC 85.8K
- Earning Date
- PRAX 08-12-2025
- ATLC 08-07-2025
- Dividend Yield
- PRAX N/A
- ATLC N/A
- EPS Growth
- PRAX N/A
- ATLC 21.75
- EPS
- PRAX N/A
- ATLC 5.17
- Revenue
- PRAX $8,122,000.00
- ATLC $424,877,000.00
- Revenue This Year
- PRAX N/A
- ATLC $273.30
- Revenue Next Year
- PRAX $4,434.72
- ATLC $11.92
- P/E Ratio
- PRAX N/A
- ATLC $9.74
- Revenue Growth
- PRAX 270.02
- ATLC 17.71
- 52 Week Low
- PRAX $26.70
- ATLC $25.44
- 52 Week High
- PRAX $91.83
- ATLC $64.70
- Technical
- Relative Strength Index (RSI)
- PRAX 78.36
- ATLC 39.47
- Support Level
- PRAX $53.89
- ATLC $45.74
- Resistance Level
- PRAX $59.10
- ATLC $53.12
- Average True Range (ATR)
- PRAX 3.26
- ATLC 2.48
- MACD
- PRAX 0.59
- ATLC -0.63
- Stochastic Oscillator
- PRAX 88.19
- ATLC 32.73
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.